Oncorus is developing potent oncolytic immunotherapies for malignant and benign tumors
Robust Viral Potency
γ34.5 retained for WT replication & IDO inhibition
gB:NT mutation to enhance target cell entry
MULTIPLE IMMUNE-MODULATORY PAYLOADS
Large 25kb capacity enables integration of multiple payloads capable of recruiting all arms of the immune system.
Tumor Matrix Modification
Matrix metalloproteinases degrade the extracellular matrix and facilitate viral spread, enhancing efficacy.
MIR CONTROLLED REPLICATION & PAYLOAD EXPRESSION
Engineering of miR-T cassettes into critical replication genes allows robust replication in tumor tissues; arming genes expressed in tumor only, increasing potency & limiting toxicity.
Targeted Viral Entry
Retargeted glycoproteins enables selective uptake by cells expressing tumor antigens.